Karen Montgomery-Douglas | Commercial Development Manager | BSc (Biomedical), Grad. Dip. Medical Laboratory Science
Karen brings over 20 years’ experience in sales and business development in the clinical trials and laboratory sectors. With a strong background in managing global and Asia-Pacific sales strategies, Karen drives growth and fosters client relationships across the pharmaceutical and biotechnology industries. She has demonstrated leadership in developing robust business processes to support commercial objectives.
Over the last 25 years, my career has evolved in various roles and I have held senior positions in the pharma/biotech industry and with international CROs. Comprehensive knowledge and experience in Clinical Operations, experience from First in Human up until late stage. Global experience, understanding the nuances of operating in a diverse environment. Strong leadership skills, with experience in a managerial role. Medical background and advanced IT skills in Trial Management Systems, EDC and e-TMF
My aim is to make the people who report to me feel that they are a valued member of a successful team, doing meaningful work in an environment of trust.
Fox Walker has been a defence analyst with GlobalData Plc for the past year. In his role, Fox helps clients navigate the return of great-power competition and understand the ways emerging military technologies are shaping the character of war. Prior to joining GlobalData, Fox earned an MA from the Department of War Studies at King’s College London. Fox is originally from Fort Worth, Texas and graduated from the University of Texas at Austin.
Rob Knight, Atto’s Chief Product & Technology Officer (CPTO), brings a wealth of expertise as a seasoned leader in organisations at the forefront of credit risk. With a strong background in Operations, Product, and Engineering leadership, Rob has championed far-reaching innovation for tech giants and spearheaded impactful digital transformations.
During his time at Experian as the Solution Development & Data Management Director, he played a pivotal role in shaping EMEA propositions and driving technology shifts, particularly within credit bureau services and large-scale transformation projects. Working across many other sectors, Rob has a constant desire to deliver the promise of innovation for the benefit of the business and the consumers enabled within the industry.
Rob brings the best of his experience from broadcast, telecommunications, geospatial, energy and financial services in the quest to transform credit & risk decisioning with open banking technology.
Kris joined TFS in August 2024, bringing nearly 40 years of clinical research experience to the Oncology and Rare Diseases business unit. Within her role, Kris manages a global team of experts ranging from physicians to clinical specialists and is responsible for supporting the project delivery of all oncology and rare disease programs.
Kris’s diverse experience spans working with CROs, pharmaceutical companies, and academic institutions, with more than half of her career focusing on oncology and rare diseases. Her extensive background includes leadership positions as Vice President of Operations, Executive Director of Strategy, and Head of Project Management, among other clinical roles across the industry.
She is deeply committed to improving the patient’s journey, particularly for those seeking life-altering and life-saving therapies through clinical trials. Her expertise in patient recruitment, retention, and study visit design allows her to provide valuable guidance to her team and sponsors, ensuring the highest quality in operational execution and deliverables in these complex therapeutic areas.
Carl Bjartmar, M.D., Ph.D. CEO and co-founder of BjartmarMed AB. Experienced global pharma and biotech executive providing medical, scientific, and operational consulting expertise to private equity and small/medium companies in drug development, business development and due diligence. Key expertise clinical development within orphan, neuromuscular, neurology and oncology indications. Solid record of global leadership, including two IPOs on Nasdaq OMX, agreed clinical plans with FDA, EMA and PMDA, successful completion of phase I-IV studies, and new drug approvals. Between 2015 and 2018 Chief Medical Officer at Wilson Therapeutics AB, Stockholm, Sweden (acquisition by Alexion Pharmaceuticals in 2018 at 70% premium – USD 850m). Chief Medical Officer at Augustine Therapeutics, Leuven, Belgium. Board member of iCoat Medical AB. More than 30 international publications (peer-reviewed articles, review articles, book chapters).
Kris Booth is the Director of Strategic Partnerships and is responsible for aligning the strategic relationships between CROs, Sponsors, and EmVenio Research. He also assists in the reviewing and implementing of commercial processes in coordination with site operations. Mr. Booth joined EmVenio Research in 2024 with a decade of experience in clinical trial project management and partner relations.
